New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Research capsule: GanedenBC30 probiotic, Pycnogenol and CoQ10 combo PycnoQ10

Recent studies reveal promise for GanedenBC30 in reducing the severity of colitis and for pycnogenol/CoQ10 combination  PycnoQ10 in managing heart failure.

Ganeden Biotech

Ganeden Biotech, GanedenBC30® (Bacillus coagulans GBI-30 6086) probiotic

STUDY CLAIM: GanedenBC30® has prolonged the survival of, and improved the stool consistency of, C. difficile-induced colitis in mice.

PUBLISHED: Fitzpatrick LR, et al. Bacillus Coagulans GBI-30 (BC30) improves indices of Clostridium difficile-Induced colitis in mice. Gut Pathog. 2011 Oct 20;3(1):16.

ABSTRACT: Researchers have found that GanedenBC30®, a probiotic (beneficial bacteria), has prolonged the survival of, and improved the stool consistency of, C. difficile-induced colitis in mice. Clostridium difficile, often referred to as C. difficile, is a bacterium that causes inflammation of the colon, known as colitis. People who have other illnesses or conditions requiring prolonged use of antibiotics, and the elderly, are at greater risk of acquiring C. difficile. In the study female mice were dosed by oro-gastric gavage for 15 days with vehicle (saline) or BC30 (2 × 109 CFU per day). Mice in the C. difficile groups received an antibiotic mixture (study days 5 to 8 in the drinking water), and clindamycin (10 mg/kg, i.p., on study day 10). The C. difficile strain VPI 10463 was given by gavage at 104 CFU to induce colitis on day 11. On day 12, a significant difference (p = 0.0002) in the percentage of mice with normal stools (66.7 percent) was found in the BC30/C. difficile group, as compared to the vehicle/C. difficile group (13.0 percent). On study day 16, 23.8 percent of mice treated with BC30 had normal stools, while this value was 0 percent with vehicle treatment (p value = 0.0187).

“Some previous clinical studies focused on combined treatment with vancomycin and probiotics,” said Leo R. Fitzpatrick, PhD, lead principal investigator of the study and Associate Professor of Pharmacology at Penn State College of Medicine. “But in this study, administering only GanedenBC30 to C. difficile-infected mice resulted in an improvement in the consistency of their stool and reduction in the severity of the disease.”

POTENTIAL APPLICATIONS:  While most strains of good bacteria need to be delivered in capsule form, Ganeden’s BC30 probiotic delivery system is different—it can be consumed in a variety of foods and beverages such as muffins, yogurt, bars, and even tea.


Pycnogenol®, French maritime pine bark extract

Pycnogenol®, French maritime pine bark extract and Coenzyme Q10 combination, PycnoQ10®

STUDY CLAIM: After supplementing with PycnoQ10® and prescribed heart medication, patients experienced increased blood volume output, improved physical fitness and blood pressure, as well as heart and respiratory rate.

PUBLISHED: Belcaro G., et al. Investigation of Pycnogenol® in combination with coenzymeQ10 in heart failure patients (NYHA II/III). PANMINERVA MED 2010;52(Suppl. 1 to No 2):21-5.

ABSTRACT: Researchers investigated benefits of a Pycnogenol­® –coenzyme Q10 combination (PycnoQ10®) taken as an adjunct to medical treatment in stable heart failure patients. The aim of this single-blinded, 12-week observational study was to provide functional parameters such as exercise capacity, ejection fraction and distal edema.

The essential element for inclusion was a stable level of heart failure within the past three months and stable NYHA class II or III (6 months). The mean age of the PycnoQ10®-treated patients was 61.3±7.1 years and 62.1±3.7 in the control group. All patients were taking medication and most patients (>75 percent) used three or more drugs for heart failure treatment.

Nine PycnoQ10® treated patients (out of 32) and 3 (out of 21) taking placebo improved NYHA class. Systolic and diastolic pressure as well as heart rate and respiratory rate were significantly lowered with PycnoQ10® as compared to the control group (P<0.05). No significant changes were observed in controls. Heart ejection fraction increased by 22.4 percent in the treatment group (P<0.05) versus 4.0 percent in controls. Walking distance on treadmill increased 3.3-fold in PycnoQ10® treated patients (P<0.05) but marginally improved in the control group. Distal edema decreased significantly in PycnoQ10® treated patients and only slightly in controls.

POTENTIAL APPLICATIONS: The association of Pycnogenol® and CoQ10 may offer an important therapeutic option with a very good tolerability that improves heart failure management without side effects.

[email protected]

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.